CNS Pharmaceuticals
Seeks to acquire or in-license neurology and oncology drug candidates.
Something off on this page? Send us feedback.
Profile
Seeks to acquire or in-license neurology and oncology assets while offering its legacy Berubicin and TPI 287 programs for out-licensing. Pre-revenue operations are funded through capital-market transactions and depend on external development, manufacturing and regulatory execution.
Searches globally for differentiated preclinical or clinical-stage neurology and oncology assets to acquire or in-license, with biological rationale, defined development paths and near-term milestones central to selection. The intended model is lean and capital-efficient, with clinical, regulatory and manufacturing work planned during diligence.
Separately seeks out-licensees for its legacy glioblastoma programs: Berubicin, a second-generation anthracycline and topoisomerase-II inhibitor, and TPI 287, a blood-brain-barrier-permeable microtubule inhibitor. Neither is a marketed product; Berubicin's randomized study did not establish overall-survival superiority, and TPI 287 rights are limited to the United States, Canada, Mexico and Japan.
Operates without product revenue and funds activities through capital-market transactions, while relying on external research, manufacturing and development providers. Advancing either new or legacy programs depends on asset rights, clinical development, regulatory approval and counterparties.
Company facts
Key statistics
Year to date +4.2% · Average volume (30d) 8.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Sep 12, 2025 | Maxim Group | Upgrade | Hold | Buy |
| Mar 25, 2025 | Maxim Group | Downgrade | Buy | Hold |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.24 | −$0.38 | −58.3% | — | — | — | −8.91% |
| May 14, 2026Q1 FY26 | −$5.37 | −$7.30 | −35.9% | — | — | — | −1.20% |
| Mar 31, 2026Q4 FY25 | −$5.09 | −$5.09 | 0.0% | — | — | — | −4.60% |
| Nov 14, 2025Q3 FY25 | −$6.63 | −$5.76 | +13.1% | — | — | — | −2.90% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | −$1.1K | −$1.1K | −$697 | $2.9K | −$1.9K | $0 | |
| Operating income | −$4.3M | −$2.4M | −$3.3M | −$6.0M | −$5.0M | −$2.7M | |
| Net income | −$4.3M | −$2.4M | −$3.2M | −$6.0M | −$4.9M | −$2.6M | |
| Diluted EPS | −$18.93 | −$6.42 | −$5.76 | −$10.15 | −$7.30 | −$0.38 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $20.0M · Total debt $0 · Total assets $21.9M · Shareholders' equity $18.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 1.46M · Float 1.45M · 99.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Stonepine Capital Management, LLC | 159.8K | 9.90% | 13G | May 15, 2026 |
| Ikarian Capital, LLC | 45.8K | 5.70% | 13G | Apr 17, 2026 |
| Geode Capital Management, LLC | 23.2K | 1.59% | 13F | May 15, 2026 |
| Boothbay Fund Management, LLC | 13.5K | 0.93% | 13F | May 15, 2026 |
| Faith L. Charles · director | 7.1K | 0.49% | Form 4 | May 20, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 18, 2026 | Michal Fisher | director | +2,000 | $5.00 |
| May 18, 2026 | Faith L. Charles | director | +7,100 | $4.79 |
Peers
- Fortress Biotech
Direct rival in GBM programs and in-licensing of development assets.
- Roivant Sciences
Rival buyer of development assets and builder of drug platforms.
- Ligand Pharmaceuticals
Scaled royalty aggregator competing for external clinical assets.
- Novartis (ADR)
Scaled oncology and neuroscience buyer with global development reach.
- Biogen
Neurology franchise and active dealmaker for development-stage assets.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CNS Pharmaceuticals | $5.75 | +4.11% | $8.1M | — | — | — | — |
| Fortress Biotech | $2.76 | −0.47% | $92.0M | 1.0 | — | 1.3 | +14.0% |
| Roivant Sciences | $34.44 | −0.72% | $25.07B | — | — | 3,329.1 | −33.6% |
| Ligand Pharmaceuticals | $280.49 | −0.04% | $5.62B | 30.0 | 27.2 | 19.3 | +33.7% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Biogen | $218.19 | −0.14% | $32.28B | 38.7 | 16.5 | 3.2 | +3.4% |
| Median | 26.6 | 16.5 | 5.3 | +3.4% |